Recent News

• 02.09.2026 - Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
• 01.16.2026 - Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
• 01.09.2026 - Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
• 11.19.2025 - Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
• 11.19.2025 - Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

Recent Filings

• 02.06.2026 - 8-K Current report
• 01.20.2026 - 8-K Current report
• 01.16.2026 - 8-K Current report
• 01.14.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.07.2026 - EFFECT Notice of Effectiveness
• 01.02.2026 - POS AM Post-Effective amendments for registration statement
• 12.17.2025 - 8-K Current report
• 12.17.2025 - EX-99.1 EX-99.1
• 12.05.2025 - 8-K Current report
• 11.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]